Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) insider Gabriel Brooks sold 2,923 shares of the company's stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $6.50, for a total transaction of $18,999.50. Following the completion of the sale, the insider now owns 10,979 shares of the company's stock, valued at approximately $71,363.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Solid Biosciences Trading Down 2.1 %
Solid Biosciences stock opened at $5.70 on Wednesday. The company has a market capitalization of $220.02 million, a P/E ratio of -1.73 and a beta of 1.90. Solid Biosciences Inc. has a 1-year low of $1.81 and a 1-year high of $15.05. The firm's fifty day simple moving average is $7.73 and its 200-day simple moving average is $8.13.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.05. On average, equities research analysts predict that Solid Biosciences Inc. will post -2.61 earnings per share for the current year.
Wall Street Analyst Weigh In
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Several brokerages have recently commented on SLDB. Barclays decreased their target price on Solid Biosciences from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Wednesday, August 14th. William Blair raised shares of Solid Biosciences to a "strong-buy" rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. raised shares of Solid Biosciences from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $10.00 to $15.00 in a research report on Monday, July 15th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $15.67.
Get Our Latest Research Report on SLDB
Hedge Funds Weigh In On Solid Biosciences
Institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in Solid Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company's stock valued at $402,000 after buying an additional 5,287 shares during the last quarter. American Century Companies Inc. boosted its holdings in Solid Biosciences by 39.9% during the second quarter. American Century Companies Inc. now owns 34,557 shares of the company's stock valued at $196,000 after acquiring an additional 9,853 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Solid Biosciences in the second quarter valued at about $58,000. Ground Swell Capital LLC acquired a new position in shares of Solid Biosciences during the 2nd quarter worth about $76,000. Finally, Algert Global LLC bought a new stake in Solid Biosciences during the 2nd quarter valued at approximately $82,000. Institutional investors own 81.46% of the company's stock.
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
